| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
1 Department of Medicine, The University of Liverpool, Liverpool, UK
2 Birmingham Heartlands Hospital, Birmingham, UK
3 St George’s Hospital Medical School, London, UK
4 Department of Medical Statistics, GlaxoSmithKline R&D, UK
Correspondence to:
Correspondence to:
Professor P M A Calverley, Clinical Science Centre, University Hospital Aintree, Liverpool L9 7AL, UK;
pmacal{at}liverpool.ac.uk
Background: A limited or absent bronchodilator response is used to classify chronic obstructive pulmonary disease (COPD) and can determine the treatment offered. The reliability of the recommended response criteria and their relationship to disease progression has not been established.
Methods: 660 patients meeting European Respiratory Society (ERS) diagnostic criteria for irreversible COPD were studied. Spirometric parameters were measured on three occasions before and after salbutamol and ipratropium bromide sequentially or in combination over 2 months. Responses were classified using the American Thoracic Society/GOLD (ATS) and ERS criteria. Patients were followed for 3 years with post-bronchodilator FEV1 and exacerbation history recorded 3 monthly and health status 6 monthly.
Results: FEV1 increased significantly with each bronchodilator, a response that was normally distributed. Mean post-bronchodilator FEV1 was reproducible between visits (intraclass correlation 0.93). The absolute change in FEV1 was independent of the pre-bronchodilator value but the percentage change correlated with pre-bronchodilator FEV1 (r=-0.44; p<0.0001). Using ATS criteria, 52.1% of patients changed responder status between visits compared with 38.2% using ERS criteria. Smoking status, atopy, and withdrawing inhaled corticosteroids were unrelated to bronchodilator response, as was the rate of decline in FEV1, decline in health status, and exacerbation rate.
Conclusion: In moderate to severe COPD bronchodilator responsiveness is a continuous variable. Classifying patients as "responders" and "non-responders" can be misleading and does not predict disease progression.
Keywords: chronic obstructive pulmonary disease; bronchodilator reversibility
Relevant Article
Thorax 2003 58: 647.
This article has been cited by other articles:
|
|
 |
|
  R. Dal Negro, M. Visconti, F. Trevisan, S. Bertacco, C. Micheletto, and S. Tognella Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 271 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Vestbo COPD, diagrams and traditions: time to move on? Thorax, September 1, 2008; 63(9): 755 - 756. [Full Text] [PDF]
|
|
|
|
|
|
S E Marsh, J Travers, M Weatherall, M V Williams, S Aldington, P M Shirtcliffe, A L Hansell, M R Nowitz, A A McNaughton, J B Soriano, et al. Proportional classifications of COPD phenotypes Thorax, September 1, 2008; 63(9): 761 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kainu, A. Lindqvist, S. Sarna, B. Lundback, and A. Sovijarvi FEV1 Response to Bronchodilation in an Adult Urban Population Chest, August 1, 2008; 134(2): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Mannino Coexisting Asthma and COPD: Confused Clinicians or Poor Prognosticator? Chest, July 1, 2008; 134(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wood and R. A. Stockley Editorial: Unifying the genetics, co-morbidities and management of COPD Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 113 - 117. [PDF]
|
|
|
|
 |
|
 M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hizawa, H. Makita, Y. Nasuhara, T. Betsuyaku, Y. Itoh, K. Nagai, M. Hasegawa, and M. Nishimura {beta}2-Adrenergic Receptor Genetic Polymorphisms and Short-term Bronchodilator Responses in Patients With COPD Chest, November 1, 2007; 132(5): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Makita, Y. Nasuhara, K. Nagai, Y. Ito, M. Hasegawa, T. Betsuyaku, Y. Onodera, N. Hizawa, M. Nishimura, and the Hokkaido COPD Cohort Study Group Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease Thorax, November 1, 2007; 62(11): 932 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Hanania and J. F. Donohue Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes, C. La Vecchia, L. M. Fabbri, M. Duerden, Y. Kupfer, S. Tessler, N. Keaney, P. Calverley, J. Anderson, and B. Celli Prevention of Death in COPD N. Engl. J. Med., May 24, 2007; 356(21): 2211 - 2214. [Full Text] [PDF]
|
|
|
|
|
|
L Shahab, M J Jarvis, J Britton, and R West Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample Thorax, December 1, 2006; 61(12): 1043 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Walker, P. Mitchell, F. Diamantea, C. J. Warburton, and L. Davies Effect of primary-care spirometry on the diagnosis and management of COPD Eur. Respir. J., November 1, 2006; 28(5): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Laszlo Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force Thorax, September 1, 2006; 61(9): 744 - 746. [Full Text] [PDF]
|
|
|
|
|
|
A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD Chest, June 1, 2006; 129(6): 1693 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Herpel, R. E. Kanner, S. M. Lee, H. E. Fessler, F. C. Sciurba, J. E. Connett, R. A. Wise, and for the Lung Health Study Research Group and the N Variability of Spirometry in Chronic Obstructive Pulmonary Disease: Results from Two Clinical Trials Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1106 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. M. Wouters Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several? Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Leigh, M. M. M. Pizzichini, M. M. Morris, F. Maltais, F. E. Hargreave, and E. Pizzichini Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Eur. Respir. J., May 1, 2006; 27(5): 964 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. van Noord, J. L. Aumann, E. Janssens, J. Verhaert, J. J. Smeets, A. Mueller, and P. J. G. Cornelissen Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD Chest, March 1, 2006; 129(3): 509 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Stevenson, P. P. Walker, R. W. Costello, and P. M. A. Calverley Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Beta2 agonist reversibility testing in COPD diagnosis DTB, December 1, 2005; 43(12): 89 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Hansen and J. Vestbo Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness? Eur. Respir. J., July 1, 2005; 26(1): 6 - 7. [Full Text] [PDF]
|
|
|
|
|
|
N. R. Anthonisen, P. G. Lindgren, D. P. Tashkin, R. E. Kanner, P. D. Scanlon, J. E. Connett, and for the Lung Health Study Research Group Bronchodilator response in the lung health study over 11 yrs Eur. Respir. J., July 1, 2005; 26(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kostikas, M. Gaga, G. Papatheodorou, T. Karamanis, D. Orphanidou, and S. Loukides Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma Chest, May 1, 2005; 127(5): 1553 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. van der Woude, J. Zaagsma, D. S. Postma, T. H. Winter, M. van Hulst, and R. Aalbers Detrimental Effects of {beta}-Blockers in COPD: A Concern for Nonselective {beta}-Blockers Chest, March 1, 2005; 127(3): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ruffin Peak expiratory flow (PEF) monitoring Thorax, November 1, 2004; 59(11): 913 - 914. [Full Text] [PDF]
|
|
|
|
|
|
T. S. Lapperre, J. B. Snoeck-Stroband, M. M.E. Gosman, J. Stolk, J. K. Sont, D. F. Jansen, H. A.M. Kerstjens, D. S. Postma, and P. J. Sterk Dissociation of Lung Function and Airway Inflammation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 499 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.J. Sterk From the Editor Eur. Respir. J., August 1, 2004; 24(2): 332 - 333. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Donohue Therapeutic Responses in Asthma and COPD: Bronchodilators Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Mapel Treatment Implications on Morbidity and Mortality in COPD Chest, August 1, 2004; 126(2_suppl_1): 150S - 158S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Sutherland and R. M. Cherniack Management of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., June 24, 2004; 350(26): 2689 - 2697. [Full Text] [PDF]
|
|
|
|
|
|
P.M.A. Calverley and S.I. Rennard Application of management guidelines to the assessment of new medicines: driving us forward or holding us back? Eur. Respir. J., June 1, 2004; 23(6): 793 - 794. [Full Text] [PDF]
|
|
|
|
|
|
A. D. D'Urzo and P. M. A. Calverley Withdrawal of Treatment in the ISOLDE Study Chest, June 1, 2004; 125(6): 2368 - 2368. [Full Text] [PDF]
|
|
|
|
|
|
P M A Calverley Breathlessness during exercise in COPD: how do the drugs work? Thorax, June 1, 2004; 59(6): 455 - 457. [Full Text] [PDF]
|
|
|
|
|
|
W D C Man, N Mustfa, D Nikoletou, S Kaul, N Hart, G F Rafferty, N Donaldson, M I Polkey, and J Moxham Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD Thorax, June 1, 2004; 59(6): 471 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Molfino Genetics of COPD Chest, May 1, 2004; 125(5): 1929 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.J. Sterk Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1 Eur. Respir. J., April 1, 2004; 23(4): 497 - 498. [Full Text] [PDF]
|
|
|
|
|
|
D Halpin NICE guidance for COPD Thorax, March 1, 2004; 59(3): 181 - 182. [Full Text] [PDF]
|
|
|
|
|
|
J E Cotes and P M A Calverley Bronchodilator reversibility testing in COPD * Authors' reply Thorax, February 1, 2004; 59(2): 178 - 179. [Full Text] [PDF]
|
|
|
|
|
|
P S Burge and S A Lewis So inhaled steroids slow the rate of decline of FEV1 in patients with COPD after all? Thorax, November 1, 2003; 58(11): 911 - 913. [Full Text] [PDF]
|
|
|
|
|
|
N J Gross Responses to steroids and bronchodilators in COPD in the ISOLDE trial: the fat lady sings on Thorax, August 1, 2003; 58(8): 647 - 648. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
